PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Despite the clinical success of blocking its interactions, how PD-1 inhibits T-cell activation is incompletely understood, as exemplified by its potency far exceeding what might be predicted from its affinity for PD-1 ligand-1 (PD-L1). This may be partially attributed to PD-1's targeting the proximal signaling of the T-cell receptor (TCR) and co-stimulatory receptor CD28 via activating Src homology region 2 domain-containing phosphatases (SHPs). Here, we report PD-1 signaling regulates the initial TCR antigen recognition manifested in a smaller spreading area, fewer molecular bonds formed, and shorter bond lifetime of T cell interaction with peptide-major histocompatibility complex (pMHC) in the presence than absence of PD-L1 in a manner dependent on SHPs and Leukocyte C-terminal Src kinase. Our results identify a PD-1 inhibitory mechanism that disrupts the cooperative TCR-pMHC-CD8 trimolecular interaction, which prevents CD8 from augmenting antigen recognition, explaining PD-1's potent inhibitory function and its value as a target for clinical intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“CTLA4 disrupted the ZAP70 cluster formation in most T cells, although 5%‐10% of T cells demonstrated cluster forming followed by anti‐CD3 treatment [302, 303, 304].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [303]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Advanced methods of microscope control using μManager software
D. Edelstein, A., A. Tsuchida, M., Amodaj, N., Pinkard, H., D. Vale, R., & Stuurman, N. (2014) · Journal of Biological Methods · doi:10.14440/jbm.2014.36 · Cited by 1,909
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689
T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1
Dustin, M. L., & Springer, T. A. (1989) · Nature · doi:10.1038/341619a0 · Cited by 1,538
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910 · cited 1×
“The imaging surface was then prepared in the following incubation steps with three washes using PBS after each step: (1) coating with 50 μg/ml biotinylated bovine serum albumin (BSA); (2) coating with streptavidin; (3) coating with mixture of biotinylated pMHC and biotinylated antiPentaHis (Qiagen) or biotinylated ant…”
Method
Cited by
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
“1 Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China 2 Department of Radiation Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China inhibiting some early activating pathways o…”
BackgroundTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Chu, X., Tian, W., Wang, Z., Zhang, J., & Zhou, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01800-3 · Cited by 220
“While, other co-inhibitory molecules such as PD-1, interfere with processes further downstream in the signaling cascade [37].”
BackgroundTargeting the tumor microenvironment: Potential strategy for cancer therapeutics
Babar, Q., Saeed, A., Tabish, T. A., Sarwar, M., & Thorat, N. D. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166746 · Cited by 125
CD8+ T cell-based cancer immunotherapy
Chen, Y., Yu, D., Qian, H., Shi, Y., & Tao, Z. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05134-6 · Cited by 130
“For instance, the interaction between TCR and PD-1 had a negative regulatory role in T cell antigen recognition [133, 134].”
Background
Metadata
- Authors
- Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C.
- Affiliations
- Georgia Institute of Technology (US)
- Emory University (US)
- John Radcliffe Hospital (GB)
- Corresponding author
- Zhu, Cheng
- Venue
- Nature Communications
- Published
- 2021-05-12
- Volume
- 12
- Issue
- 1
- Pages
- 2746-2746
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8115078
- OpenAlex
- W3163417555
- Cited by
- 81
- References
- 77
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 18 · 2023: 21 · 2022: 11 · 2021: 5
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA214354, R01CA243486, U01CA250040)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PD-1, PD-L1, T cell activation, CD28, SHP2, Lck, antigen recognition, T cell receptor signaling, immune checkpoint blockade
- MeSH terms
- Animals, Calcium, Humans, Lymphocyte Activation, Major Histocompatibility Complex, Mice, Transgenic, Protein Binding, Receptors, Antigen, T-Cell, T-Lymphocytes, Signal Transduction, CD8 Antigens, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition. https://app.cochat.ai/papers/10.1038/s41467-021-22965-9
- The paper
- Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C. (2021). PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition. Nature Communications. https://doi.org/10.1038/s41467-021-22965-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.